Litifilimab BIIB059 Systemic Lupus Erythematosus Study
Study overview
This Phase 3 clinical trial evaluates litifilimab, also identified in study materials as BIIB059, in adults with active systemic lupus erythematosus. The randomized, double-blind, placebo-controlled design compares study groups while participants continue protocol-permitted background nonbiologic standard-of-care treatment. Randomization is used to assign treatment, and masking limits knowledge of group assignment during the controlled period to reduce bias in the assessment of outcomes.
What researchers are evaluating
Researchers are evaluating whether litifilimab changes lupus disease activity and are monitoring its safety and tolerability. Study procedures may include examinations, disease-activity questionnaires and scoring, medication reviews, blood and urine testing, pregnancy testing when applicable, electrocardiograms, and monitoring for infections or other adverse events. Litifilimab is investigational for this use, so its benefits and risks are not fully established. The protocol defines permitted background medicines, restricted treatments, visit schedules, and rules for responding to changes in disease activity.
Considering participation
Eligibility may depend on age, a documented SLE diagnosis, measurable disease activity, laboratory findings, current medications, prior biologic therapy, infection history, vaccinations, pregnancy-related requirements, and other medical conditions. Screening is performed by authorized study staff using the current protocol; it does not guarantee enrollment. Study status can change, and this educational page does not confirm that a local cohort is accepting participants. Participation is voluntary. Before enrollment, the team explains study groups, procedures, foreseeable risks, possible benefits, alternatives, privacy protections, and participant rights. An individual may discuss the study with a rheumatology clinician, family, or another trusted adviser. Do not include records, insurance details, or sensitive health information in an initial inquiry.